Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 5,936

Document Document Title
WO/2009/004146
The invention relates to products having formula (I), in which A represents one of the following three rings: ring a, ring b, ring c and W represents hydrogen or -(C1-C4)alkyl, -(C1-C4)alkenyl, -CO-(C1-C3)alkyl, - CO-(C1-C3)alkenyl, -CO-...  
WO/2009/005033
It is intended to provide a substance which can be used as an active ingredient for improving dysfunction due to neuropathy. An agent for improving dysfunction due to neuropathy of the invention as a means for resolution is characterized...  
WO/2009/001915
Disclosed is a novel substituted imidazole compound having excellent renin inhibitory activity, which is sufficiently practical for use as a pharmaceutical product. Specifically disclosed is a compound represented by the formula (I) belo...  
WO/2008/155390
This invention relates to the use of inhibitors of sirtuins and/or AMPK for the preparation of a medicament for the treatment of polyalanine diseases, in particular oculopharyngeal musculardystrophy (OPMD). The invention also relates to ...  
WO/2008/156685
The invention relates to tendon stem cells useful for treating a variety of diseases and condition, including tendon repair and attachment of tendon to bone. The invention is also directed to treatment and/or inhibition of bone formation...  
WO/2008/156513
Disclosed herein are compositions and methods for the treatment of skeletal muscle and/or the protection of skeletal muscle against injury. The adenosine A3 receptor has been identified as a new therapeutic target for the treatment of sk...  
WO/2008/156418
The present invention relates to methods for screening or diagnosis of Postpolio Syndrome (PPS) in subjects, for determining the stage or severity of PPS, for identifying subjects at risk of developing PPS, or for monitoring the effect o...  
WO/2008/156685
The invention relates to tendon stem cells useful for treating a variety of diseases and condition, including tendon repair and attachment of tendon to bone. The invention is also directed to treatment and/or inhibition of bone formation...  
WO/2008/156513
Disclosed herein are compositions and methods for the treatment of skeletal muscle and/or the protection of skeletal muscle against injury. The adenosine A3 receptor has been identified as a new therapeutic target for the treatment of sk...  
WO/2008/155390
This invention relates to the use of inhibitors of sirtuins and/or AMPK for the preparation of a medicament for the treatment of polyalanine diseases, in particular oculopharyngeal musculardystrophy (OPMD). The invention also relates to ...  
WO/2008/156513
Disclosed herein are compositions and methods for the treatment of skeletal muscle and/or the protection of skeletal muscle against injury. The adenosine A3 receptor has been identified as a new therapeutic target for the treatment of sk...  
WO/2008/149177
Novel marine lipid compositions comprising triglycerides and omega-3 rich phospholipids are described. The compositions are characterized by providing highly bioavailable omega- 3, increased tissue incorporation of omega-3 and reduced co...  
WO/2008/150477
The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.  
WO/2008/149177
Novel marine lipid compositions comprising triglycerides and omega-3 rich phospholipids are described. The compositions are characterized by providing highly bioavailable omega- 3, increased tissue incorporation of omega-3 and reduced co...  
WO/2008/150477
The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.  
WO/2008/148867
The present invention relates to quinoxaline compound of the formula (I): wherein R1 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R; R2 is caryl or heterocyclyl, either of which is option...  
WO/2008/148867
The present invention relates to quinoxaline compound of the formula (I): wherein R1 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R; R2 is caryl or heterocyclyl, either of which is option...  
WO/2008/150525
The invention provides anti-Notch 1 NRR antibodies, and compositions comprising and methods of using these antibodies.  
WO/2008/138943
The invention relates to the use of sirtuin inhibitors for reducing TNF-alpha production by cells and organisms. The invention also concerns prophylactic and therapeutic applications of sirtuin inhibitors in TNF-alpha mediated pathologie...  
WO/2008/138115
A nutritional composition comprising at least L-carnitine fumarate, red wine extract, and saw palmetto extract is provided to maintain skeletal muscle androgen receptivity, via simultaneous increase in the availability of androgen recept...  
WO/2008/138943
The invention relates to the use of sirtuin inhibitors for reducing TNF-alpha production by cells and organisms. The invention also concerns prophylactic and therapeutic applications of sirtuin inhibitors in TNF-alpha mediated pathologie...  
WO/2008/140782
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds ...  
WO/2008/140782
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds ...  
WO/2008/138115
A nutritional composition comprising at least L-carnitine fumarate, red wine extract, and saw palmetto extract is provided to maintain skeletal muscle androgen receptivity, via simultaneous increase in the availability of androgen recept...  
WO/2008/135661
The invention relates to the use of L-citrulline of the formula (I) for preparing a cosmetic composition, a food or nutraceutic composition or a pharmaceutical composition for treating diseases related to an increase in protein carbonyla...  
WO/2008/134844
The present invention relates to compositions and methods for improving skeletal muscle protein metabolism through encouraging skeletal muscle protein synthesis, reducing skeletal muscle protein degradation, and attenuating inflammatory ...  
WO/2008/135661
The invention relates to the use of L-citrulline of the formula (I) for preparing a cosmetic composition, a food or nutraceutic composition or a pharmaceutical composition for treating diseases related to an increase in protein carbonyla...  
WO/2008/131941
The present invention relates to a method of treating a movement disorder in a patient, the method comprising administering a medicament comprising an effective amount of chemodenervating agent to said patient, wherein said patient is su...  
WO/2008/133132
Disclosed is a method for improving the activity of a reactive oxygen species (ROS)-scavenging enzyme, which has a mechanism of action based on scientific grounds, is highly safe, is inexpensive, and is widely applicable. An organism hav...  
WO/2008/126693
It is intended to provide a remedy and a diagnostic for a brain disease typified by cerebral infarction. Namely, a remedy for a mitochondrial dysfunction brain disease characterized by comprising a combination of (A) a δ-aminolevulinic ...  
WO/2008/122098
The biological function of skeletal muscle precursor cells in the repair and growth of skeletal muscle in response to exercise is promoted by providing a supplemental composition comprising at least creatine and fucoidin to reinforce bio...  
WO/2008/119571
Myostatin antagonists are used to treat muscular generative disorders, type 2 diabetes or obesity. The antanogists are nucleic acid molecules capable of binding to myostatin.  
WO/2008/120761
A compound represented by the following general formula [1] or a pharmaceutically acceptable salt thereof. [Chemical formula 1] [1] In the general formula [1], one of X and Y represents CH and the other represents oxygen or sulfur; R rep...  
WO/2008/120778
It is intended to provide a composition for promoting the formation of a ketone compound which contains a water-soluble β-hydroxy short to medium chain fatty acid polymer. This composition for promoting the formation of a ketone compoun...  
WO/2008/119571
Myostatin antagonists are used to treat muscular generative disorders, type 2 diabetes or obesity. The antanogists are nucleic acid molecules capable of binding to myostatin.  
WO/2008/116665
The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin-4 receptor antagonists. The antagonists are useful for the treatment of disorders and d...  
WO/2008/112238
The present invention provides methods of treating chronic pain, in particular, neuropathic pain, chronic visceral pain, chronic inflammatory pain and pain resulting from fibromyalgia syndrome, in a subject by administering Dimebon™ an...  
WO/2008/108322
The present invention relates to a composition for protecting mitochondria from damage in a mammalian subject which comprises a specific prostaglandin compound. The present invention also relates to a pharmaceutical composition for treat...  
WO/2008/108322
The present invention relates to a composition for protecting mitochondria from damage in a mammalian subject which comprises a specific prostaglandin compound. The present invention also relates to a pharmaceutical composition for treat...  
WO/2008/105392
Disclosed is a substance for inhibiting cell death, which is effective as a prophylactic or therapeutic agent for the progress of a condition of a disease whose of progress or exacerbation is associated with cell death. Specifically disc...  
WO/2008/105526
Disclosed is a new class of compound which has HSP90 inhibitory activity and is useful as an antitumor agent or the like. Also disclosed is a compound which is useful as a synthesis intermediate for the compound having HSP90 inhibitory a...  
WO/2008/102749
Disclosed is a compound which has an ACC-inhibiting activity, which is useful for the prevention/treatment of obesity, diabetes, hypertension, hyperlipemia, heart failure, complications of diabetes, metabolic syndrome, sarcopenia, cancer...  
WO/2008/102372
The present invention relates to a novel herbal composition for improving exercise physiology factors comprising saponins and sugar derivatives optionally along with pharmaceutically acceptable excipients. It also relates to the process ...  
WO/2008/101313
The present invention describes compounds produced from an amino acid molecule and a fatty acid molecule. The compounds being in the form of amino-fatty acid compounds being bound by an amide linkage, or mixtures thereof made by reacting...  
WO/2008/101824
The present invention relates to a compound of the formula (I) in which: R1 is a hydrogen atom or a C1- C6 alkoxy group; R2 is a hydrogen atom or a C1- C6 alkyl group optionally substituted by a hydroxy group; R3 is a hydrogen atom, a C1...  
WO/2008/096769
PPARγ activators/modulators which contain as the active ingredient cercosporamide derivatives represented by the general formula (I) or pharmacologically acceptable salts or esters thereof; and pharmaceutical compositions for the treatm...  
WO/2008/095356
Methods for treating SMA in a subject comprise administering to the subject a recombinant genetic vector comprising at least one copy of a Stathmin inhibitor. The inhibitor can be a Stathmin expression inhibitor. The inhibitor can be or ...  
WO/2008/096755
Disclosed is a novel vanilloid receptor (VR1) inhibitor which can be used as an effective therapeutic agent for an acute pain and/or a chronic pain which has less adverse side effects and can be used safely. The vanilloid receptor (VR1) ...  
WO/2008/095357
Compositions for treatment of spinal muscular atrophy (SMA) and methods for use thereof to treat SMA and other conditions of SMN-deficiency; novel drug development targets for SMA therapies, and methods of use thereof to screen for candi...  
WO/2008/090940
Disclosed are: a pharmaceutical agent which is effective on a disease induced by the over-response of Th2 or Th17 (e.g., multiple sclerosis); and a method for efficient screening of the pharmaceutical agent. Specifically disclosed are: a...  

Matches 701 - 750 out of 5,936